[Clinical study of a new oral anti-inflammatory: Zami 642].
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy* / Q000601:surgery; D010447:Peptide Hydrolases / Q000627:therapeutic use; D011402:Pronase / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D007933:Leucomycins; D010447:Peptide Hydrolases; D011402:Pronase; C026483:midecamycin; C022640:serratiopeptidase
Sperimentazione clinica di un nuovo antinfiammatorio orale: Zami 642.